This test is used to determine the susceptibility of yeast isolates to antifungal agents. Interpretive criteria are provided for certain organism/drug combinations based on clinical data from infections with Candida spp. Note that the intermediate category provides a buffer zone to limit errors associated with inherent variability in the test method. Strains with intermediate MICs might respond clinically to a higher-than-standard dose of a drug or in situations in which drug penetration is maximized.